EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort

Michael R Ardern-Jones iD, Hang T T Phan, Florina Borca, Matt Stammers, James Batchelor, Isabel C Reading, Sophie V Fletcher, Trevor Smith, Andrew S Duncombe

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0280079 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Michael R Ardern-Jones und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Experimental Sciences, University of Southampton Faculty of Medicine, Sir Henry Wellcome Laboratories, Southampton General Hospital, Southam…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The success of early dexamethasone therapy for hospitalised COVID-19 cases in treatment of Sars-CoV-2 infection may predominantly reflect its anti-inflammatory action against a hyperinflammation (HI) response. It is likely that there is substantial heterogeneity in HI responses in COVID-19.

Methods

Blood CRP, ferritin, neutrophil, lymphocyte and platelet counts were scored to assess HI (HI5) and combined with a validated measure of generalised medical deterioration (NEWS2) before day 2. Our primary outcome was 28 day mortality from early treatment with dexamethasone stratified by HI5-NEWS2 status.

Findings

Of 1265 patients, high risk of HI (high HI5-NEWS2) (n = 367, 29.0%) conferred a strikingly increased mortality (36.0% vs 7.8%; Age adjusted hazard ratio (aHR) 5.9; 95% CI 3.6–9.8, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSARS-CoV-2COVID-19 TestingCOVID-19 Drug TreatmentAnti-Inflammatory AgentsDexamethasone

Substanzen

Anti-Inflammatory AgentsDexamethasone

Autor:innen und Institutionen

  • Clinical Experimental Sciences, University of Southampton Faculty of Medicine, Sir Henry Wellcome Laboratories, Southampton General Hospital, Southampton, United Kingdom.
  • Division of Medicine, University Hospitals Southampton NHS Foundation Trust, Southampton General Hospital, Southampton, United Kingdom.
  • NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Clinical Informatics Research Unit Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Department of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, United Kingdom.
  • Department of Respiratory Medicine, University Hospitals Southampton NHS Foundation Trust, Southampton, United Kingdom.

ORCID-Profile: Michael R Ardern-Jones

Zitieren

APA

Ardern-Jones, M. R., Phan, H. T. T., Borca, F., Stammers, M., Batchelor, J., Reading, I. C., Fletcher, S. V., Smith, T., & Duncombe, A. S. (2023). A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort. PLOS ONE. https://doi.org/10.1371/journal.pone.0280079

Vancouver

Ardern-Jones MR, Phan HTT, Borca F, Stammers M, Batchelor J, Reading IC, et al. A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort. PLOS ONE. 2023. doi:10.1371/journal.pone.0280079

BibTeX
@article{ArdernJones2023,
  author = {Ardern-Jones, Michael R and Phan, Hang T T and Borca, Florina and Stammers, Matt and Batchelor, James and Reading, Isabel C and Fletcher, Sophie V and Smith, Trevor and Duncombe, Andrew S},
  title = {A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0280079}
}
Kostenlos starten →